Ogkologos

4396 ΔΗΜΟΣΙΕΥΣΕΙΣ 0 ΣΧΟΛΙΑ

How to Find the Right Hospice Care Program for You or...

Ogkologos - 10 Αυγούστου, 2023

Targeted Drug Combo May Change Care for Rare Brain Tumor Craniopharyngioma

Ogkologos - 10 Αυγούστου, 2023

EMA Recommends Granting a Conditional Marketing Authorisation for Talquetamab

Ogkologos - 10 Αυγούστου, 2023

Adjuvant Everolimus Does Not Improve Recurrence-Free Survival Among Patients with Renal...

Ogkologos - 9 Αυγούστου, 2023

Research with integrity – all the fun of the FAIR

Ogkologos - 8 Αυγούστου, 2023

What to Know About Exercising During Prostate Cancer: An Expert Q&A

Ogkologos - 8 Αυγούστου, 2023

Niraparib Plus Abiraterone Acetate and Prednisone Improves rPFS and Other Clinically...

Ogkologos - 8 Αυγούστου, 2023

HER2 Expression is a Determinant of Sensitivity to Trastuzumab Deruxtecan in...

Ogkologos - 7 Αυγούστου, 2023

FDA Approves New Initial Treatment Option for Some Metastatic Prostate Cancers

Ogkologos - 4 Αυγούστου, 2023

EMA Recommends Granting a Marketing Authorisation for Tislelizumab

Ogkologos - 4 Αυγούστου, 2023

1...116117118...440 Σελίδα 117 από 440

MOST POPULAR

Speaking for Scotland: What our Scottish Campaigns Ambassadors want in a...

24 Αυγούστου, 2022

FDA Approves Azacitidine for Newly Diagnosed Juvenile Myelomonocytic Leukaemia

2 Ιουνίου, 2022

FDA Approves Acalabrutinib with Venetoclax for CLL or SLL

4 Μαρτίου, 2026

Opinion: ‘Wales needs more than a three-page statement to get cancer...

22 Μαρτίου, 2021

Φόρτωση περισσοτέρων

How to Find the Right Hospice Care Program for You or...

Targeted Drug Combo May Change Care for Rare Brain Tumor Craniopharyngioma

EMA Recommends Granting a Conditional Marketing Authorisation for Talquetamab

Adjuvant Everolimus Does Not Improve Recurrence-Free Survival Among Patients with Renal...

Research with integrity – all the fun of the FAIR

What to Know About Exercising During Prostate Cancer: An Expert Q&A

Niraparib Plus Abiraterone Acetate and Prednisone Improves rPFS and Other Clinically...

HER2 Expression is a Determinant of Sensitivity to Trastuzumab Deruxtecan in...

FDA Approves New Initial Treatment Option for Some Metastatic Prostate Cancers

EMA Recommends Granting a Marketing Authorisation for Tislelizumab

MOST POPULAR

Speaking for Scotland: What our Scottish Campaigns Ambassadors want in a...

FDA Approves Azacitidine for Newly Diagnosed Juvenile Myelomonocytic Leukaemia

FDA Approves Acalabrutinib with Venetoclax for CLL or SLL

Opinion: ‘Wales needs more than a three-page statement to get cancer...

HOT NEWS

Patients Treated With Chemotherapy and B Cell–Targeting Agents Show Impaired Serological...

At 3-Year Follow-Up Nivolumab Plus Chemotherapy Continued to Demonstrate OS Improvement...

How to Plan a ‘Safecation’

EMA Recommends Extending Indications for Pembrolizumab to Include Adjuvant Treatment in...

ΔΗΜΟΦΙΛΕΊΣ ΘΈΣΕΙΣ

ΚΑΡΚΙΝΟΣ ΘΥΜΟΥ ΑΔΕΝΑ (ΘΥΜΩΜΑ)

ΣΤΑΤΙΣΤΙΚΑ

ΚΕΝΤΡΙΚΟΥ ΝΕΥΡΙΚΟΥ ΣΥΣΤΗΜΑΤΟΣ

ΔΗΜΟΦΙΛΗ ΚΑΤΗΓΟΡΙΑ